GLAXOSMITHKLINE PHARMA A/S: Financial statements 2025
CVR: 27394019
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
GLAXOSMITHKLINE PHARMA A/S (CVR 27394019) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 580,769,000 and a net result of DKK 13,123,000 compared with DKK 12,240,000 the year before. That is an increase of 5.9% compared with the year before. The profit margin was 2.3%. Equity in the 2025 report amounted to DKK 39,017,000. The solvency ratio was 32.3%. The company had 71,000 employees in the financial year.
- Revenue
- DKK 580,769,000
- Gross Profit
- DKK 118,765,000
- Profit/Loss
- DKK 13,123,000
- Equity
- DKK 39,017,000
- Total Assets
- DKK 120,705,000
- Employees
- 71,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 580.8M | 118.8M | 13.1M | 39M | 71000 |
| 2024 | 548.5M | 134.5M | 12.2M | 38.1M | 73 |
| 2023 | 474.5M | 119.8M | 12M | 37.9M | 72 |
| 2022 | 440.3M | 126.2M | 11.1M | 36.9M | 68 |
| 2021 | 445.9M | 111.6M | 9M | 34.8M | 66 |
Official annual report
How creditworthy is GLAXOSMITHKLINE PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
GLAXOSMITHKLINE PHARMA A/S has won the tender "Amgros 2026 2.212.a" issued by Amgros I/S worth 10,566,595 DKK.
GLAXOSMITHKLINE PHARMA A/S has won the tender "Amgros 2026 1.1574.a" issued by Amgros I/S worth 734,400,000 DKK.
GLAXOSMITHKLINE PHARMA A/S has won the tender "Amgros 2026 1.1475.a" issued by Amgros I/S worth 863,100,000 DKK.
GLAXOSMITHKLINE PHARMA A/S has won the tender "Amgros 2026 1.810.a" issued by Amgros I/S worth 137,104,621 DKK.
As of August 26, 2025, Diederik Maarten Eijsvogel has joined the board of directors of GLAXOSMITHKLINE PHARMA A/S.
As of August 26, 2025, Dominika M Wiktor-Brown has left the board of directors of GLAXOSMITHKLINE PHARMA A/S.
As of August 26, 2025, Diederik Maarten Eijsvogel is registered as director of GLAXOSMITHKLINE PHARMA A/S.
As of August 26, 2025, Dominika M Wiktor-Brown has stepped down as director of GLAXOSMITHKLINE PHARMA A/S.
GLAXOSMITHKLINE PHARMA A/S has published its annual report for 2024. Revenue came to DKK 548,470,000, and the net result was DKK 12,240,000.
As of June 18, 2025, Luciano Alves de Andrade has joined the board of directors of GLAXOSMITHKLINE PHARMA A/S.
About GLAXOSMITHKLINE PHARMA A/S
GLAXOSMITHKLINE PHARMA A/S is a Danish company of the type Aktieselskab based in Vallensbæk Strand, founded in 1968. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named GLAXO DANMARK A/S and GLAXO WELLCOME A/S. The management consists of Diederik Maarten Eijsvogel. The board consists of Luciano Alves de Andrade (chair), Alastair William Jones, Diederik Maarten Eijsvogel and Helle Ann Hellberg. The company is owned by Setfirst Limited. The company has 83 employees (2026). In 2025, the company reported revenue of DKK 580,769,000 and a net result of DKK 13,123,000 compared with DKK 12,240,000 the year before. Equity in the 2025 report amounted to DKK 39,017,000.